GlassScriptPhysician profile
Chancellor E Donald
NPI 1487690376
$9,688.69
in general payments reported to CMS, 2019-2025
21 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,115 · 2020: $335 · 2021: $1,241 · 2024: $167 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,675 · Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,675.00 |
| Food and Beverage | $322.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,768.98 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $3,134.05 | 2020-2025 | Tagrisso |
| Lilly USA, LLC | $172.25 | 2020-2021 | |
| Eisai INC. | $153.83 | 2019 | |
| Astellas Pharma US INC | $95.98 | 2024-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $77.22 | 2019 | |
| Merck Sharp & Dohme LLC | $48.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.78 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.94 | 2024 | Lifevest |
| Emmaus Medical, INC. | $24.14 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.49 | 2019 | |
| Amgen INC. | $21.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.70 | 2019 | |
| Stemline Therapeutics INC. | $16.75 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $14.44 | 2019 | |
| Partner Therapeutics, INC. | $13.91 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Tesaro, INC. | $11.80 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chancellor Donald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.